XML 363 R36.htm IDEA: XBRL DOCUMENT
v3.26.1

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Revenue |
Schedule of revenue recognized | The following schedule entails detailed information about the Group’s revenue in the financial year 2025:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue from contracts with customers |  | ​ |  | ​ |  | ​
Fee for services and FTE-based research services |  | 468,515 |  | 144,412 |  | 612,927
Material re-charges to customers |  | 31,892 |  | — |  | 31,892
Milestone fees |  | 9,615 |  | — |  | 9,615
Licenses |  | 7,314 |  | 115,031 |  | 122,345
Other fees |  | 300 |  | — |  | 300
Total revenue from contracts with customers |  | 517,636 |  | 259,443 |  | 777,079
Timing of revenue recognition |  | ​ |  | ​ |  | ​
At a point in time |  | 49,121 |  | 115,031 |  | 164,152
Over a period of time |  | 468,515 |  | 144,412 |  | 612,927
Total revenue from contracts with customers | ​ | 517,636 | ​ | 259,443 | ​ | 777,079
Revenue from contributions | ​ | 11,294 | ​ | — | ​ | 11,294
Total Revenue |  | 528,930 |  | 259,443 |  | 788,373
​ ​ The following schedule entails detailed information about the Group’s revenue in the financial year 2024:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue from contracts with customers |  | ​ |  | ​ |  | ​
Fee for services and FTE-based research services |  | 553,963 |  | 183,431 |  | 737,394
Material re-charges to customers |  | 38,578 |  | — |  | 38,578
Milestone fees |  | 2,871 |  | — |  | 2,871
Licenses |  | 3,130 |  | — |  | 3,130
Other fees |  | 544 |  | — |  | 544
Total revenue from contracts with customers |  | 599,086 |  | 183,431 |  | 782,517
Timing of revenue recognition |  | ​ |  | ​ |  | ​
At a point in time |  | 83,157 |  | 44,123 |  | 127,280
Over a period of time |  | 515,929 |  | 139,308 |  | 655,237
Total revenue from contracts with customers | ​ | 599,086 | ​ | 183,431 | ​ | 782,517
Revenue from contributions | ​ | 12,308 | ​ | 2,142 | ​ | 14,450
Total Revenue |  | 611,394 |  | 185,573 |  | 796,967
​ The following schedule entails detailed information about the Group’s revenue in the financial year 2023:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Discovery & | ​ | ​ | ​ | ​
​ | ​ | Preclinical | ​ | Just - Evotec | ​ | ​
in k€ | ​ ​ ​ | Development | ​ ​ ​ | Biologics | ​ ​ ​ | Evotec Group
Revenue from contracts with customers |  | ​ |  | ​ |  | ​
Fee for services and FTE-based research services |  | 619,437 |  | 107,492 |  | 726,929
Material re-charges to customers |  | 37,561 |  | — |  | 37,561
Milestone fees |  | 4,785 |  | — |  | 4,785
Licenses |  | 674 |  | 1 |  | 675
Other fees |  | 2,059 | ​ | — |  | 2,059
Total revenue from contracts with customers |  | 664,516 |  | 107,493 |  | 772,009
Timing of revenue recognition |  | ​ |  | ​ |  | ​
At a point in time |  | 42,345 |  | 46,242 |  | 88,587
Over a period of time |  | 622,171 |  | 61,251 |  | 683,421
Total revenue from contracts with customers |  | 664,516 | ​ | 107,493 | ​ | 772,009
Revenue from contributions | ​ | 8,461 | ​ | 956 | ​ | 9,417
Total Revenue | ​ | 672,977 |  | 108,449 |  | 781,426
​
Schedule of transaction price allocated to the remaining performance obligation | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
in k€ | ​ ​ ​ | December 31, 2025 | ​ ​ ​ | December 31, 2024* | ​ ​ ​ | December 31, 2023
In the course of the following year |  | 258,618 | ​ | 460,835 |  | 571,825
After one year |  | 190,240 | ​ | 885,577 |  | 335,427
*Change from prior year disclosed amount
Schedule of contract assets and contract liabilities | ​
​ | ​ | ​ | ​ | ​
in k€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024
Balance as of January 1 |  | 46,034 |  | 25,000
Additions |  | 263,025 |  | 201,016
Reclassifications to trade receivables due to invoicing |  | (275,559) |  | (181,469)
Translation differences and other |  | (5,205) |  | 1,487
Balance as of December 31 |  | 28,295 |  | 46,034
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Current | ​ ​ ​ | Non-current
in k€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ | 2025 | ​ ​ ​ | 2024
Balance as of January 1 | ​ ​ ​ | 106,599 | ​ ​ ​ | 97,587 | ​ ​ ​ | 156,679 | ​ ​ ​ | 155,287
Additions |  | 141,168 |  | 220,121 |  | 69,649 |  | 94,574
Reduction due to recognition of revenue |  | (222,724) |  | (303,748) |  | — |  | —
Divestment of affiliated companies | ​ | — | ​ | (1,069) | ​ | — | ​ | —
Reclassification from non-current to current |  | 81,004 |  | 93,181 |  | (81,004) |  | (93,182)
Translation differences and other |  | (1,198) |  | 526 |  | — |  | —
Balance as of December 31 |  | 104,849 |  | 106,599 |  | 145,324 |  | 156,679
​

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 120 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 108 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 108 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 118 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration